Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) CEO Craig A. Wheeler sold 2,778 shares of the company’s stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $13.72, for a total transaction of $38,114.16. Following the sale, the chief executive officer now directly owns 23,330 shares of the company’s stock, valued at approximately $320,087.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of MNTA traded up $0.35 during mid-day trading on Wednesday, reaching $13.84. The stock had a trading volume of 271,700 shares, compared to its average volume of 570,655. Momenta Pharmaceuticals, Inc. has a 52-week low of $9.55 and a 52-week high of $32.20. The firm has a market capitalization of $1.36 billion, a P/E ratio of -6.82 and a beta of 2.17.
Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.45) by ($0.01). Momenta Pharmaceuticals had a negative net margin of 231.49% and a negative return on equity of 43.98%. The firm had revenue of $4.11 million during the quarter, compared to analysts’ expectations of $10.12 million. During the same period in the prior year, the company posted ($0.63) EPS. The company’s revenue for the quarter was down 15.3% compared to the same quarter last year. As a group, equities analysts anticipate that Momenta Pharmaceuticals, Inc. will post -1.68 EPS for the current year.
A number of equities research analysts recently issued reports on the stock. Zacks Investment Research lowered shares of Momenta Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, April 29th. BidaskClub raised shares of Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, March 29th. Cantor Fitzgerald set a $16.00 price objective on shares of Momenta Pharmaceuticals and gave the company a “hold” rating in a report on Thursday, May 2nd. Finally, BTIG Research assumed coverage on shares of Momenta Pharmaceuticals in a report on Monday, March 18th. They issued a “neutral” rating and a $14.15 price objective for the company. Six research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $22.23.
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.
See Also: Green Investing
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.